Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
Status:
Recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an
experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone
to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a
multicenter international set-up within the Nordic Multiple Myeloma Study Group
Phase:
Phase 2
Details
Lead Sponsor:
Ida Bruun Kristensen
Collaborators:
Karyopharm Therapeutics Inc Odense Patient Data Explorative Network